Wandercraft announces FDA clearance for personal exoskeleton

NEW YORK – Wandercraft has today that the U.S. Food and Drug Administration (FDA) has granted clearance for Eve, its personal self-balancing exoskeleton designed to support upright mobility in everyday life. For eligible wheelchair users, the clearance opens new possibilities beyond rehabilitation, bringing hands-free upright mobility into ordinary moments, the company says. “FDA clearance of Eve marks one of the most important moments in Wandercraft’s history and a significant step for the people, families, clinicians, researchers, and partners who helped make it possible,” said Matthieu Masselin, co-founder and CEO of Wandercraft. “Together, Atalante X and Eve may offer eligible users a pathway from walking during rehabilitation to upright mobility at home, whether making coffee at the kitchen counter, reaching for a book, or spending time with friends on the patio.” Wandercraft plans to commercially launch Eve in the United States on Sept. 17, 2026, as part of an exclusive event at the Cure healthcare innovation campus in New York City, presented with the United Spinal Association, which is celebrating its 80th anniversary. The livestreamed program will bring together people living with spinal cord injuries, caregivers, clinicians, researchers, policymakers and Eve pilots to mark the transition of self-balancing exoskeleton technology from rehabilitation to personal use. National Seating & Mobility (NSM) will become Wandercraft’s exclusive CRT distribution partner for Eve, using its national network of more than 180 locations to support evaluation, education, access and delivery to eligible individuals with spinal cord injuries and other severe mobility impairments. Other distribution partners include Walk US, Good Shepherd Rehabilitation and USVetServe.